Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
eNq9mF1v2jAUhu/5FVHukwClFKZAtTG6IbUao6BNu0EmOYCZsVN/ULpfP4fQDSZHbQ3eVZTYec+Jz+vHR4mvt2vibYALzGjHr4VV3wOasBTTRcefjG+Cln/drcQrtEEH067Calir+15CkBAdPx8NZ4CoCL/f3X4E/T5wv1vxYjZbQSKP5imJSfgZieUdyvI5XrxhOPXWIJcs7fiZkrunXiwk11l0Hxn/KTKUQBztnxyOrqaNw+dxlIu9QlUJ4LeILoyiQK00E8U5UNlDEhaMP5Xke2GljcUIBFM8gSGSyyFnG5xCagwxR0SAVZD5Y3oPfENA5kGM4tEqWQsrcbRC2xE8DMxJv9ejPbmVQTWoXTXb7fpVo1W9qDetQvGDpTJXQX9ElExrzUar3W5HQKM1LLTFAn0BPYeRQN9JXcggBct6DRmXiDiqFBa9Y7M5isPh4UVHpFhkBD2FK5HZLhXiSA8D10hw9yH5F4y5hhTRa/aPPlWERG/MerJHiKOMc0L1mKKyhCQ3I9uF6DEqYVteUTv4ye3eixjE+WR/MWoG/1DNCE5sMadBpPRGn4wG5ZRzDYgPSMCEuyPEN0xT9ijOT57DSjvKPtvB0yia8bQ2rbdbzdrlpfXG+qFtVXIS9RVnGUSaSVicgpoBnbNTIaOdapZ69qlTi+56JJYgAiVdUmDJIO3N56bOmfvd7axiwCj6qT+2tcxXBfzpfndrlMZp50+x7QDtgvraoKWJv93uxa530j8rbqbJUspMvIuiJRKBQHqFwjn/L/Q/OITddfNOTvqi8ykI6ij1WXE0vr5itrvupT7g1N52//6+hzbGkFzBCXUoAO0Mo4P++cn8t7F1lvbwiCTuwuyaUCQxo64aITUzKp52Fui60huu4fBlPsclf1ZKfRlHxV+dbiWO8j863cpv0wv/sA==
CzZ4YsGBaKn84zeb
Listen
